|
HHS Global Health Collaborative
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
NIMH
|
This interagency working group meets to provide a forum within the Department of Health and Human Services (HHS) that identifies Global Health issues relevant to the HHS Global mental health agenda.
|
|
HHS Health Disparities Council
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA, OS, SAMHSA
|
NIMHD
|
The Department of Health and Human Services (HHS) Health Disparities Council serves as the venue to share information, leverage HHS investments, coordinate HHS activities, reduce program duplication, and track progress on the strategies and actions of the HHS Disparities Action Plan.
|
|
HHS HIV Bidirectional Meeting Planning Committee
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA, OS, SAMHSA
|
NIAID, NIMH
|
Planning committee for June, 26 2019 meeting for the Department of Health and Human Services (HHS) global and domestic policy and program leaders to share successful strategies and lessons learned, and to discuss potential adaptations to enable the transfer/implementation of proven strategies among new environments.
|
|
HHS Kidney Care Work Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, OS
|
NIAID
|
The goals of the Department of Health and Human Services (HHS) Kidney Care Work Group are to 1) reduce the number of new patients needing organ transplants by 25% by 2030; 2) provide healthier options for those on life-saving protocols so that 80 % of dialysis patients can be treated by alternatives to current dialysis by 2025; and 3) expand the supply of organs 3 fold by 2025.
|
|
HHS LGBT Policies Coordinating Committee
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ATSDR, CDC, CMS, FDA, HRSA, IHS, OS, OSG, SAMHSA
|
OD/DPSCSI/SGMRO, NIMH
|
The Department of Health and Human Services (HHS) Lesbian, Gay, Bisexual and Transgender (LGBT) Policy Coordinating Committee is comprised of senior representatives from each division of HHS. This committee coordinates the exchange of information about LGBT-related policies across the department, and provides a mechanism for both collecting and disseminating this information across operating divisions.
|
|
HHS Noise-Induced Hearing Loss Federal Partner Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NIDCD
|
Work group to coordinate and collaborate the Department of Health and Human Services (HHS) activities and messages related to noise-induced hearing loss. Federal partners include the National Institutes of Health (NIH) National Institute on Deafness and Other Communication Disorders and the Centers for Disease Control and Prevention (CDC) National Center for Environmental Health and National Institute for Occupational Safety and Health.
|
|
HHS Office on Women’s Health, Section on Pregnancy and Newborn Care
|
Committee, Work group, Advisory group, or Task Force
|
OS, SAMHSA
|
NICHD, NIMH
|
The National Institutes of Health (NIH) scientists work together with other Department of Health and Human Services (HHS) experts to develop and reviewcontent for HHS public-facing websites, including the womenshealth.gov website.
|
|
HHS Open Innovation Community of Practice
|
Meeting/ Workshop
|
ACF, AHRQ, CDC, CMS, FDA, HRSA, IHS, SAMHSA
|
NCI, NIDA, NIDDK, NIEHS, NLM
|
Workshop to highlight open innovation work performed and/or supported by the Department of Health and Human Services (HHS) staff, and to plot a course forward for the HHS open innovation community. Community of Practice is continuation of activities began at the workshop.
|
|
HHS Panel for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NICHD, OD/DPCPSI/OAR
|
This committee has the purpose of updating the U.S. Pediatric opportunistic infection prevention and treatment guidelines for HIV-Exposed and HIV-Infected Children and serves as executive secretary. These guidelines are developed by a panel of specialists in pediatric HIV infection and infectious diseases (the Panel on Opportunistic Infections in HIV-Exposed and HIV-Infected Children) from the U.S. government and academic institutions. The Panel is a working group of the Office of AIDS Research Advisory Council. For each OI, one or more pediatric specialists with subject-matter expertise reviews the literature for new information since the last guidelines were published, and then proposes revised recommendations for review by the full Panel. After these reviews and discussions, the guidelines undergo further revision, with review and approval by the Panel, and final review and endorsement by the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA), and the Pediatric Infectious Disease Society (PIDS). The Panel also received input from the American Academy of Pediatrics (AAP).
|
|
HHS Panel on Antiretroviral Guidelines for Adults and Adolescents
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA, HRSA
|
NICHD, NIAID, OD/DPCPSI/OAR
|
The Department of Health and Human Services (HHS) Panel on Antiretroviral Guidelines for Adults and Adolescents (the Panel) is a working group of the Office of AIDS Research Advisory Council (OARAC). The primary goal of the Panel is to provide HIV care practitioners with recommendations based on current knowledge of antiretroviral drugs (ARVs) used to treat adults and adolescents with HIV in the United States. The Panel reviews new evidence and updates recommendations when needed. These guidelines include recommendations on baseline laboratory evaluations, treatment goals, benefits of ART and considerations
when initiating therapy, choice of the initial regimen for ART-naive patients, ARV drugs or combinations to avoid, management of treatment failure, management of adverse effects and drug interactions, and special ART-related considerations in specific patient populations.
|